Clinical Trials
85
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (79 trials with phase data)• Click on a phase to view related trials
EMBRACE Tremor BiFUS
- Conditions
- Essential Tremor
- First Posted Date
- 2025-05-16
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- InSightec
- Target Recruit Count
- 100
- Registration Number
- NCT06974916
- Locations
- 🇩🇪
Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH), Kiel, Germany
🇮🇹Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
🇪🇸HM CINAC- Hospital Universitario HM Puerta del Sur, Móstoles, Spain
A Prospective, Randomized, Controlled Trial to Test Safety and Effectiveness of Unilateral Exablate MR-guided Focused Ultrasound Subthalamotomy in Patients With Early-Stage Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Procedure: Exablate MRgFUS subthalamotomyDrug: Best Medical Treatment
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- InSightec
- Target Recruit Count
- 72
- Registration Number
- NCT06584383
- Locations
- 🇨🇱
Pontificia Universidad Catolica de Chile, Santiago, Chile
🇩🇪Universitätsklinikum Schleswig-Holstein, Campus Kiel (UKSH), Kiel, Germany
🇪🇸HM CINAC- Hospital Universitario HM Puerta del Sur, Móstoles, Spain
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InSightec
- Target Recruit Count
- 10
- Registration Number
- NCT05630209
- Locations
- 🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸Nicklaus Children's Hospital, Miami, Florida, United States
Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG
- First Posted Date
- 2022-11-14
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- InSightec
- Target Recruit Count
- 10
- Registration Number
- NCT05615623
- Locations
- 🇨🇦
Sunnybrook Research Institute, Toronto, Ontario, Canada
MR-guided Focused Ultrasound Plus GCase
- Conditions
- Parkinsons Disease
- First Posted Date
- 2022-10-04
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- InSightec
- Target Recruit Count
- 14
- Registration Number
- NCT05565443
- Locations
- 🇨🇦
Sunybrook Research Institute, Toronto, Ontario, Canada
- Prev
- 1
- 2
- 3
- 4
- 5
- 17
- Next
News
Insightec Receives FDA Approval for Bilateral Focused Ultrasound Treatment in Advanced Parkinson's Disease
The FDA has approved Insightec's Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients with advanced Parkinson's disease, expanding therapeutic options for over 50,000 patients.
Genomic Testing Emerges as Critical Tool in Brain Cancer Treatment, Experts Emphasize
Comprehensive genomic profiling is crucial for brain cancer patients, enabling personalized treatment approaches and identification of actionable mutations like NTRK fusions, according to Dr. Manmeet Ahluwalia.
Insightec's Exablate Prime Receives FDA Approval for Use with Philips MRI Systems
Insightec's Exablate Prime system has gained FDA approval and CE mark for integration with select Philips MRI systems, expanding access to non-invasive treatments.
Insightec's Exablate Prime Receives FDA and CE Mark for Philips MRI Integration
Insightec's Exablate Prime system has been approved by the FDA and has received CE Mark for integration with select Philips MRI systems, expanding access to focused ultrasound treatments.
MRI-Guided Ultrasound Shows Promise for Bilateral Essential Tremor Treatment
A multi-center clinical trial demonstrates the safety and efficacy of bilateral high-intensity focused ultrasound for essential tremor.
FDA Approves Insightec's Exablate Neuro for Advanced Parkinson's Disease Treatment
The FDA has approved Insightec's Exablate Neuro focused ultrasound system for treating advanced Parkinson's disease patients with mobility, rigidity, or dyskinesia symptoms through incisionless pallidotomy.
Focused Ultrasound Successfully Opens Blood-Brain Barrier in ALS Patients: Groundbreaking Trial Results
Sunnybrook researchers have demonstrated the safety of using focused ultrasound to temporarily open the blood-brain barrier in ALS patients, marking a world-first clinical achievement published in Nature Communications.